Skye Bioscience, Inc. (SKYE)
Market Cap | 11.00B |
Revenue (ttm) | n/a |
Net Income (ttm) | -37.50M |
Shares Out | 971.55M |
EPS (ttm) | -2.34 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 58,328 |
Open | 12.58 |
Previous Close | 12.07 |
Day's Range | 10.85 - 12.90 |
52-Week Range | 1.44 - 19.41 |
Beta | 1.75 |
Analysts | Buy |
Price Target | 22.50 (+98.76%) |
Earnings Date | n/a |
About SKYE
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company's lead clinical program's product candidate is nimacimab, a peripherally-restricted negative allosteric modulating antibody specific for the human cannabinoid receptor 1 (CB1) receptor, administered as a subcutaneous injectable that is Phase II clinical trials for the treatment of metabolic disorders, including obesity. It is also developing SBI-100 Ophthalmic Emulsion... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SKYE stock is "Buy." The 12-month stock price forecast is $22.5, which is an increase of 98.76% from the latest price.
News
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
Poster presentation details screening approach allowing selection of candidate molecules applicable to dry eye disease and chronic ocular pain, with potential to identify therapeutic candidates with n...
Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...
Skye Bioscience to Present at Upcoming Investment Conferences
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...
Skye Bioscience Uplists to The Nasdaq Global Market
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercial...
Skye Bioscience Announces $40 Million Private Placement Equity Financing
Financing expected to fund strategic expansion of obesity clinical development and extend operating runway beyond 2026 San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. ...
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercial...
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company”), a clinical-stage biotechnology company focused on the discovery, development and commerciali...
Skye Bioscience to Present at Oppenheimer Investor Conference
San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercializ...
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 inhibitor, in combination wi...
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity and chronic kidney disease San Francisco, California--(Newsfile...
Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab
Skye files IND with FDA Division of Diabetes, Lipid Disorders and Obesity Phase 2 study in patients with obesity and chronic kidney disease planned to initiate in first half of 2024 SAN DIEGO, Dec. 11...
Skye Bioscience Responds to OTC Markets Promotional Policy
San Diego, California--(Newsfile Corp. - December 8, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid syst...
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endoca...
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, focusing on ...
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system to address di...
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
• SBI-100 OE is well tolerated, with low rate of hyperaemia (8.4%)• Reduced intraocular pressure (23% mean reduction) in healthy volunteers with higher baseline IOP (>17 mm Hg) San Diego, California--...
CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"
Phase 1 clinical data to be released in conjunction with Investor Day This document replaces and updates the previous version with the current OTCQB ticker for Skye Bioscience, Inc. San Diego, Califor...
Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"
Phase 1 clinical data to be released in conjunction with Investor Day San Diego, California--(Newsfile Corp. - October 19, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pha...
Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial
Patient enrollment starting in Q4 2023 for proof-of-concept P2a study of CB1 agonist Phase 1 study complete and data will be reported in October San Diego, California--(Newsfile Corp. - September 27, ...
Skye Bioscience Announces Participation at Upcoming Investor Conferences
San Diego, California--(Newsfile Corp. - September 22, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical company developing proprietary medicines that modulate t...
Skye Bioscience Reverse Stock Split to Be Effective on September 8th
San Diego, California--(Newsfile Corp. - September 7, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid ...
Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference
San Diego, California--(Newsfile Corp. - September 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid ...
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
Acquisition of Bird Rock Bio builds Skye's position as a leading endocannabinoid system-focused pharmaceutical company New capital funds anticipated Phase 2a glaucoma clinical trial Nimacimab is a fir...
Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
San Diego, California--(Newsfile Corp. - August 14, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat g...
Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion
Skye preparing to start Phase 2a glaucoma clinical trial in Q3 San Diego, California--(Newsfile Corp. - July 13, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...